Table: The Race for a Cancer Treatment

COMPANY: AstraZeneca

DRUG: Iressa (pill)

TARGET: Growth signals inside the cancer cell

DISEASE: Lung cancer. Also being tested against breast, colon, gastric, and prostate cancer

STATUS: FDA application filed in Dec. 2001; decision expected in June

COMPANY: ImClone Systems

DRUG: Erbitux (intravenous injection)

TARGET: Growth-signal receptor on surface of cancer cell

DISEASE: Colon cancer. Also being tested against head and neck, pancreatic, and breast cancer

STATUS: FDA application rejected in Dec. 2001; expected to refile by yearend

    Before it's here, it's on the Bloomberg Terminal.